Abstract
To analyse the number of drugs successfully achieiving National Centre of Phamacoeconomics (NCPE) reimbursement in 2022 with non-orphan drug status compared to orphan drug status, and to identify any impacts achieving orphan drug status might have on reimbursement success.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
